A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma


Colorectal carcinoma (CRC) is the third-most commonly diagnosed cancer in the U.S., and the third-most common cause of cancer death. There were 136,830 new cases of CRC and 50,310 deaths due to CRC in 2014. For patients with unresectable metastatic disease, initial therapy commonly consists of chemotherapy combinations of Fluoropyrimidine agents… (More)


  • Presentations referencing similar topics